SIGLEC15: An Emerging Immune Checkpoint Target in Tumor ImmunotherapySIGLEC15 is an emerging immune checkpoint molecule widely expressed in various tumors, closely associated with immune evasion, treatment resistance, and poor prognosis. It plays a key role in tumor immunosuppression by i...
Detailed information

Metabolic Hub, Reprogramming Disease: SLC3A2 – From Amino Acid Transport Mechanism to Emerging Therapeutic TargetSLC3A2 (CD98hc) is far more than a typical transporter protein; it serves as a pivotal hub linking amino acid metabolism to cellular signaling. It plays a critical role in cancer, neurological, metabolic, and immune dise...
Detailed information

The "Achilles' Heel" of Cancer Stem Cells: LGR5 Becomes Focus of $8 Billion AcquisitionOn September 29, Genmab announced it had entered into an acquisition agreement with Merus to purchase all outstanding shares of the latter for $97 per share, totaling approximately $8 billion. The LGR5/EGFR bispecific an...
Detailed information

CD45: The Immune Cell "Gatekeeper" Protein – Why is it Emerging as a Novel Therapeutic Target?1. CD45 Overview CD45 (also known as PTPRC, Leukocyte Common Antigen) is a highly conserved transmembrane glycoprotein tyrosine phosphatase, widely expressed on the surface of all nucleated hematopoietic...
Detailed information

FLT1 (VEGFR-1): A Bidirectional Regulator of Angiogenesis and an Emerging Therapeutic TargetThe vascular endothelial growth factor receptor (VEGFR) family has long been a focus of therapeutic interest. Among them, FLT1 (VEGFR-1) stands out for its unique role as a "bidirectional regulator." FLT1 is far more tha...
Detailed information

Nicotinic Acetylcholine Receptor α1 Subunit (CHRNA1): Structure, Functional Mechanisms, and Disease-Related Research Progress1. Background of CHRNA1 1.1 Molecular Structure and Functional Characteristics The CHRNA1 gene is located on human chromosome 2q31.1 and encodes the α1 subunit of the nicotinic acetylchol...
Detailed information

PTPRD: The Overlooked Signaling Hub from Neurodevelopment to Cancer SuppressionProtein tyrosine phosphatase receptor type D (PTPRD) is a key member of the protein tyrosine phosphatase (PTP) family, belonging to the transmembrane receptor-type phosphatases. It precisely regulates diverse intracellul...
Detailed information

Case Study: Single B Cell Antibody Discovery Targeting TROP2The history of antibody discovery spans from von Behring and Kitasato’s concept of antitoxin (1890) [1] to Köhler and Milstein’s development of the hybridoma technique (1975) [2]. Later, phage display further advanc...
Detailed information

SEZ6: A New Therapeutic Target for Neuroendocrine Tumors with Multiple ADCs in Clinical Development1. What is SEZ6？ Seizure-related 6 homolog (SEZ6) is a transmembrane protein initially discovered due to its association with epilepsy [1]. The gene is located on chromosome 17q21.33 and encodes a prot...
Detailed information

Targeting the "Hidden Target" ROR1: A Breakthrough for Broad-Spectrum Cancer Therapy?1. What is ROR1？ Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transmembrane glycoprotein belonging to the ROR family. Its structure comprises extracellular immunoglobulin-like domains, cystei...
Detailed information